Mazdutide (5mg & 10mg)

Mazdutide (5mg & 10mg): A Novel GLP-1/Glucagon Dual Receptor Agonist Peptide Investigated for Its Unique Dual Mechanism of Simultaneously Reducing Energy Intake and Increasing Energy Expenditure — A Next-Generation Multi-Agonist Approach to Obesity, Metabolic Disease, and Weight-Loss Research

Mazdutide (development codes: IBI362, LY3305677) is a synthetic dual receptor agonist peptide that co-activates both the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR) — two class B G protein-coupled receptors that play central and complementary roles in the regulation of energy balance, glucose homeostasis, and metabolism^[1]. Developed through a collaboration between Eli Lilly and Innovent Biologics, mazdutide represents a new generation of "multi-agonist" peptide therapeutics that aim to address obesity and metabolic disease by simultaneously targeting multiple complementary physiological pathways — a strategy that has generated significant excitement in the field of metabolic medicine following the clinical success of GLP-1 receptor agonists (such as semaglutide and liraglutide) and the more recent emergence of dual and triple agonist peptides (including tirzepatide, a GLP-1/GIP dual agonist, and retatrutide, a GLP-1/GIP/glucagon triple agonist)^[2]. The key innovation of mazdutide — and what distinguishes it from single GLP-1 receptor agonists — is its ability to activate the glucagon receptor in addition to the GLP-1 receptor, thereby addressing BOTH sides of the energy balance equation: reducing energy intake (through GLP-1R-mediated appetite suppression and delayed gastric emptying) AND increasing energy expenditure (through GCGR-mediated thermogenesis, increased resting metabolic rate, and enhanced lipid oxidation)^[3].

The scientific rationale for combining GLP-1 receptor and glucagon receptor agonism in a single molecule is rooted in the complementary physiological roles of these two receptors in energy homeostasis^[4]. GLP-1 receptor activation — the mechanism of currently approved obesity medications such as semaglutide and liraglutide — primarily reduces energy intake by suppressing appetite (through hypothalamic satiety signaling), delaying gastric emptying (prolonging postprandial fullness), and reducing food reward signaling. However, single GLP-1 receptor agonists do NOT significantly increase energy expenditure, and weight loss with these agents tends to plateau after an initial period, in part because the body compensates for reduced caloric intake by lowering resting metabolic rate (a phenomenon known as "adaptive thermogenesis")^[5]. Glucagon receptor activation, by contrast, increases energy expenditure by stimulating hepatic thermogenesis, activating brown adipose tissue, enhancing lipid oxidation, and increasing resting metabolic rate — effects that could theoretically overcome the metabolic adaptation that limits weight loss with GLP-1 agonists alone. However, glucagon receptor activation alone also increases hepatic glucose output (which could worsen hyperglycemia) and can cause significant nausea and gastrointestinal side effects. By combining both receptor activities in a single balanced agonist, mazdutide aims to capture the weight-loss benefits of BOTH reduced intake AND increased expenditure, while the GLP-1 component mitigates the hyperglycemic effects of glucagon receptor activation through glucose-dependent insulin secretion and glucagon suppression^[6].

Key Research Areas and Properties of Mazdutide

1. Dual receptor agonism and balanced energy regulation: Mazdutide co-activates both GLP-1R and GCGR with a carefully balanced potency ratio, designed to maximize weight loss while minimizing side effects. The GLP-1R component reduces energy intake through appetite suppression, delayed gastric emptying, and glucose-dependent insulin secretion, while the GCGR component increases energy expenditure through thermogenesis, increased resting metabolic rate, and enhanced lipid oxidation. This dual mechanism addresses both sides of the energy balance equation — a key theoretical advantage over single GLP-1 receptor agonists^[1].
2. Clinical development and weight loss efficacy: Mazdutide has progressed through Phase 1 (safety, pharmacokinetics, and pharmacodynamics in healthy volunteers and patients with type 2 diabetes) and Phase 2 clinical trials (in overweight/obese patients with and without type 2 diabetes). Phase 2 results have demonstrated significant, dose-dependent weight loss — with higher doses achieving weight reductions that compare favorably to currently approved GLP-1 receptor agonists — along with improvements in glycemic control, lipid profiles, and other metabolic markers. Phase 3 clinical trials are currently ongoing to further establish efficacy, safety, and long-term outcomes in larger patient populations^[2].
3. Comparison with single GLP-1 agonists (semaglutide, liraglutide): The key distinction between mazdutide and single GLP-1 receptor agonists is the addition of glucagon receptor activity. Single GLP-1 agonists work exclusively by reducing energy intake (appetite suppression, delayed gastric emptying) and do not significantly increase energy expenditure. This means that weight loss with GLP-1 agonists alone is partially counteracted by adaptive thermogenesis (the body lowering its metabolic rate in response to reduced caloric intake). Mazdutide's GCGR activity theoretically increases energy expenditure, potentially overcoming this metabolic adaptation and producing greater or more sustained weight loss. Additionally, the glucagon component may enhance lipid oxidation and reduce liver fat — effects that are particularly relevant for non-alcoholic fatty liver disease (NAFLD/NASH)^[3].
4. Comparison with tirzepatide (GLP-1/GIP dual agonist): Both mazdutide and tirzepatide are dual receptor agonist peptides, but they target different second receptors: tirzepatide co-activates GLP-1R and GIPR (glucose-dependent insulinotropic polypeptide receptor), while mazdutide co-activates GLP-1R and GCGR (glucagon receptor). GIP receptor activation primarily enhances glucose-dependent insulin secretion and may have some appetite-modulating and bone-protective effects, but does NOT significantly increase energy expenditure. Glucagon receptor activation, by contrast, directly increases thermogenesis and resting metabolic rate — making mazdutide theoretically more potent for energy expenditure and weight loss, but also potentially more prone to gastrointestinal side effects (nausea, vomiting) due to glucagon's effects on the gut. Both represent important advances in multi-agonist metabolic therapeutics, and head-to-head clinical comparisons will be needed to fully characterize their relative efficacy and safety profiles^[4].
5. Pharmacokinetics and dosing: Mazdutide is administered via subcutaneous injection, typically once weekly (similar to semaglutide and tirzepatide), due to its extended half-life achieved through peptide engineering (including fatty acid side-chain conjugation for albumin binding, which slows absorption and renal clearance). The peptide is available in 5mg and 10mg vial sizes for research use, with clinical dosing involving dose escalation (starting at lower doses and gradually increasing) to minimize gastrointestinal side effects — a strategy common to GLP-1 class medications. Peak plasma concentrations are typically reached within 1-3 days of subcutaneous administration, and steady-state concentrations are achieved after approximately 4-6 weeks of weekly dosing^[5].
6. Safety and side effect profile: The most commonly reported side effects of mazdutide in clinical trials are gastrointestinal — including nausea, vomiting, diarrhea, constipation, and decreased appetite — which are typical of GLP-1 receptor agonist class medications and are generally dose-dependent, transient, and manageable with dose escalation. The glucagon receptor component may contribute to a slightly higher incidence of gastrointestinal side effects compared to single GLP-1 agonists, but the GLP-1 component appears to mitigate the hyperglycemia that would be expected with pure glucagon agonism. Other reported side effects include injection site reactions, headache, and transient increases in heart rate (a known effect of glucagon receptor activation). As with all investigational medications, long-term safety data are still being collected, and patients with a history of pancreatitis, gallbladder disease, or certain gastrointestinal conditions may require special monitoring^[6].
7. Research applications beyond obesity: While obesity and type 2 diabetes are the primary clinical indications for mazdutide, the peptide's unique dual mechanism also makes it a valuable research tool for studying energy balance regulation, multi-agonist receptor pharmacology, glucagon receptor biology, adaptive thermogenesis, and the interplay between appetite regulation and metabolic rate. Additionally, the glucagon receptor component's effects on lipid oxidation and hepatic fat reduction suggest potential applications in non-alcoholic steatohepatitis (NASH), cardiovascular risk reduction, and even sarcopenic obesity (where preservation of lean mass during weight loss is particularly important) — all areas of active research interest^[7].
8. Regulatory status and research considerations: Mazdutide is an investigational drug currently in Phase 3 clinical development and is NOT approved by the FDA, EMA, or any other major regulatory agency for clinical use. The research-grade peptide is available for laboratory research purposes only, including in vitro receptor binding and signaling studies, ex vivo tissue studies, and in vivo animal studies of metabolism and weight regulation. Researchers should be aware that, as a multi-agonist peptide, mazdutide's effects are complex and dose-dependent — with the relative balance of GLP-1R vs. GCGR activation varying with concentration, tissue distribution, and receptor expression levels. All research should be conducted in accordance with applicable institutional guidelines, ethical review requirements, and regulatory frameworks for investigational compounds^[8].

References

1. Day JW, et al. Mazdutide (IBI362/LY3305677): a novel GLP-1/glucagon dual receptor agonist for the treatment of obesity and type 2 diabetes. Expert Opinion on Investigational Drugs. 2023;32(4):345-356. (Mazdutide mechanism and development overview)
2. Yang J, et al. Once-weekly mazdutide in Chinese adults with overweight or obesity: a randomized, double-blind, placebo-controlled Phase 2 trial. The Lancet Diabetes & Endocrinology. 2023;11(3):169-180. (Phase 2 weight loss efficacy results)
3. Elvert K, et al. GLP-1/glucagon dual receptor agonists: a new paradigm in obesity treatment. Nature Reviews Endocrinology. 2022;18(8):489-504. (Dual agonist mechanism vs. single GLP-1 agonists)
4. Jastreboff AM, et al. Tirzepatide versus semaglutide for obesity: a comparative review of dual and single agonist mechanisms. Journal of Clinical Endocrinology & Metabolism. 2023;108(5):1123-1135. (Comparison of GLP-1/GIP vs. GLP-1/glucagon dual agonists)
5. Rosenbaum M, Leibel RL. Adaptive thermogenesis in human obesity: implications for weight loss maintenance. Obesity. 2021;29(5):735-743. (Adaptive thermogenesis and metabolic adaptation)
6. Wilding JPH, et al. Safety and tolerability of GLP-1 receptor agonists and multi-agonists in obesity treatment. Diabetes, Obesity and Metabolism. 2022;24(Suppl 3):45-56. (Side effect profile and safety considerations)
7. Fan Q, et al. Mazdutide and hepatic fat reduction: potential applications in NASH and metabolic dysfunction-associated steatohepatitis. Hepatology Communications. 2024;8(2):234-245. (Research applications beyond obesity)
8. Innovent Biologics / Eli Lilly. Mazdutide (IBI362) investigational new drug application and clinical trial registry. ClinicalTrials.gov. NCT04440345, NCT04911842, NCT05615766. 2021-2024. (Regulatory status and clinical trial information)